Mariane B. Melo

Aug 28, 2024 | biorxiv.org | Parisa Yousefpour |Yiming Zhang |Laura Maiorino |Mariane B. Melo

AbstractSaponin-based vaccine adjuvants are potent in preclinical animal models and humans, but their mechanisms of action remain poorly understood. Here, using a stabilized HIV envelope trimer immunogen, we carried out studies in non-human primates (NHPs) comparing the most common clinical adjuvant alum with Saponin/MPLA Nanoparticles (SMNP), a novel ISCOMs-like adjuvant.